Enphase Energy Inc vs Twist Bioscience Corp — how do they compare? Enphase Energy Inc trades at $33.24 (market cap $4.43B), while Twist Bioscience Corp trades at $157.11 (market cap $10.32B). The key difference: Twist Bioscience Corp is far larger — about 2.3× Enphase Energy Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Twist Bioscience Corp for 27 Days on average.
| ENPH | TWST | |
|---|---|---|
Market Cap | $4.43B | $10.32B |
Volume | 3,388,482 | 5,894,998 |
Sector | Energy | Health |
52-Week High | $72.33 | $205.00 |
52-Week Low | $26.12 | $25.45 |
Typical Hold Time | 72 Days | 27 Days |
Enterprise Value | $4.07B | $10.24B |
Signals from Pluang's Aura AI — not financial advice
ENPH trades at $33.50, down 1.21% on the day, with a bearish technical signal and mixed earnings history. Revenue declined to $1.47B in 2025 from $2.3B in 2023, though net income margin improved to 11.68%. Recent news includes product approvals and manufacturing milestones for AI data centers, but the stock faces pressure from high borrowing costs impacting the solar sector. The company maintains solid liquidity with $1.62B in cash, but debt levels remain elevated.
The outlook is cautious; analyst consensus is a Buy with a $42.90 price target, but recent earnings misses and sector headwinds pose risks. Upside depends on execution in AI infrastructure and EV charging, while competition and interest rate sensitivity are key concerns. The stock offers potential for recovery if operational trends stabilize.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →